SG11201809714TA - Piperidines as menin inhibitors - Google Patents
Piperidines as menin inhibitorsInfo
- Publication number
- SG11201809714TA SG11201809714TA SG11201809714TA SG11201809714TA SG11201809714TA SG 11201809714T A SG11201809714T A SG 11201809714TA SG 11201809714T A SG11201809714T A SG 11201809714TA SG 11201809714T A SG11201809714T A SG 11201809714TA SG 11201809714T A SG11201809714T A SG 11201809714TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ann arbor
- co7d
- apartment
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1111111111111111111111111111110111111111111111111111111111111111110111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/192543 Al 09 November 2017 (09.11.2017) W I P0 I P C T (51) International Patent Classification: C07D 401/04 (2006.01) A61K 31/4523 (2006.01) CO7D 401/14 (2006.01) A61K 31/454 (2006.01) CO7D 405/04 (2006.01) A61K 31/4545 (2006.01) CO7D 211/34 (2006.01) A61P 35/00 (2006.01) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (21) International Application Number: PCT/US2017/030577 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (22) International Filing Date: KM, ML, MR, NE, SN, TD, TG). 02 May 2017 (02.05.2017) (25) Filing Language: English Published: — with international search report (Art. 21(3)) (26) Publication Language: English (30) Priority Data: 62/330,350 02 May 2016 (02.05.2016) US (71) Applicant: REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Office of Technology Trans- fer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US). _ (72) Inventors: WANG, Shaomeng; 3336 Stirling Ct., Superi- or Township, MI 49198 (US). AGUILAR, Angelo; 2364 - = Stone Rd., Ann Arbor, 48105 (US). ZHANG, Ke; 2411 Stone Rd., Ann Arbor, MI 48105 (US). XU, Shilin; 3578 =_ Green Brier Blvd., Apartment 405C, Ann Arbor, MI 48105 (US). XU, Tianfeng; 2153 Arbor Circle West, Apartment 205, Ypsilanti, 48197 (US). BERNARD, Denzil; 1803 = Pointe Crossing St., Apartment 101, Ann Arbor, MI 48105 = (US). HUANG, Liyue; 3170 Otter Creek Ct., Ann Arbor, MI 48105 (US). = (74) Agent: NAPOLI, James J.; Marshall, Gerstein & Borun = LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = = = = = — = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = 1-1 en (54) Title: PIPERIDINES AS MENIN INHIBITORS in ei (57) : The present disclosure provides compounds represented by Formula (I): (Formula(I)) R3b cT - and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 2 , R 3a , R 3b , A, G, CP x , ,„ X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds IN R 3 R 2 of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer. 1-1 0 ei G O
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662330350P | 2016-05-02 | 2016-05-02 | |
PCT/US2017/030577 WO2017192543A1 (en) | 2016-05-02 | 2017-05-02 | Piperidines as menin inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809714TA true SG11201809714TA (en) | 2018-11-29 |
Family
ID=58699299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809714TA SG11201809714TA (en) | 2016-05-02 | 2017-05-02 | Piperidines as menin inhibitors |
Country Status (13)
Country | Link |
---|---|
US (2) | US10899738B2 (en) |
EP (1) | EP3452461B1 (en) |
JP (1) | JP6991585B2 (en) |
KR (1) | KR20190015275A (en) |
CN (1) | CN109415337B (en) |
AU (1) | AU2017259436B2 (en) |
BR (1) | BR112018072570A2 (en) |
CA (1) | CA3022868A1 (en) |
ES (1) | ES2899936T3 (en) |
IL (2) | IL262697B (en) |
MX (1) | MX2018013433A (en) |
SG (1) | SG11201809714TA (en) |
WO (1) | WO2017192543A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
TWI703150B (en) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | Methods and compositions for inhibiting the interaction of menin and mll proteins |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
TWI743096B (en) | 2016-03-16 | 2021-10-21 | 美商庫拉腫瘤技術股份有限公司 | Bridged bicyclic inhibitors of menin-mll and methods of use |
PT3429591T (en) | 2016-03-16 | 2023-06-21 | Univ Michigan Regents | Substituted inhibitors of menin-mll and methods of use |
CA3022868A1 (en) | 2016-05-02 | 2017-11-09 | Shaomeng Wang | Piperidines as menin inhibitors |
MX2019002959A (en) | 2016-09-14 | 2019-07-04 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction. |
EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
EP3555103B1 (en) | 2016-12-15 | 2021-09-22 | Janssen Pharmaceutica NV | Azepane inhibitors of menin-mll interaction |
CN110691779B (en) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | Method for treating hematological malignancies and ewing's sarcoma |
SG11201909083UA (en) | 2017-03-31 | 2019-10-30 | Univ Michigan Regents | Piperidines as covalent menin inhibitors |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
TW201920170A (en) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | Substituted inhibitors of MENIN-MLL and methods of use |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
JP2021519785A (en) * | 2018-03-30 | 2021-08-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Piperidine compounds as covalent menin inhibitors |
WO2019189732A1 (en) | 2018-03-30 | 2019-10-03 | 大日本住友製薬株式会社 | Optically active crosslinked cyclic secondary amine derivative |
CN113164443A (en) * | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | Treatment of hematologic malignancies with multiple endocrine oncostatin inhibitors |
CA3112340A1 (en) * | 2018-10-03 | 2020-04-09 | The Regents Of The University Of Michigan | Small molecule menin inhibitors |
AU2019417833A1 (en) * | 2018-12-31 | 2021-06-24 | Biomea Fusion, Inc. | Irreversible inhibitors of menin-MLL interaction |
TW202043205A (en) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Inhibitors of menin-mll interaction |
TW202126636A (en) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | Piperidine compounds as menin inhibitors |
TW202204334A (en) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin inhibitors and methods of use for treating cancer |
TW202204333A (en) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin inhibitors and methods of use for treating cancer |
BR112023023154A2 (en) | 2021-05-08 | 2024-01-23 | Janssen Pharmaceutica Nv | REPLACED SPIRO DERIVATIVES |
CN117730081A (en) | 2021-05-08 | 2024-03-19 | 詹森药业有限公司 | Substituted spirocyclic derivatives |
AU2022271791A1 (en) * | 2021-05-12 | 2024-01-04 | Board Of Regents, The University Of Texas System | Combinations for treatment of cancer |
AU2022286467A1 (en) | 2021-06-01 | 2024-01-25 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES |
CA3218340A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
CN117597348A (en) | 2021-06-17 | 2024-02-23 | 詹森药业有限公司 | (R) -N-ethyl-5-fluoro-N-isopropyl-2- ((5- (2- (6- ((2-methoxyethyl) (methyl) amino) -2-methylhex-3-yl) -2, 6-diazaspiro [3.4] oct-6-yl) -1,2, 4-triazin-6-yl) oxy) benzamide benzenesulfonate for the treatment of diseases such as cancer |
WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
AU7450898A (en) | 1997-05-28 | 1998-12-30 | Tokyo Tanabe Company Limited | Indole compounds |
US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
US8242078B2 (en) | 2006-10-19 | 2012-08-14 | The University Of Chicago | Therapeutics to inhibit MLL-menin interaction for treating leukemia |
EP2473054B1 (en) | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
WO2011060321A1 (en) | 2009-11-16 | 2011-05-19 | Chdi, Inc. | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof |
US9555039B2 (en) | 2011-05-09 | 2017-01-31 | Forma Tm, Llc. | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) |
CN105188705A (en) | 2013-03-13 | 2015-12-23 | 密歇根大学董事会 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
WO2014200479A1 (en) * | 2013-06-12 | 2014-12-18 | The Regents Of The University Of Michigan | Menin-mll inhibitors and methods of use thereof |
US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
TWI703150B (en) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | Methods and compositions for inhibiting the interaction of menin and mll proteins |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
US20190010167A1 (en) | 2015-12-22 | 2019-01-10 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
TWI743096B (en) | 2016-03-16 | 2021-10-21 | 美商庫拉腫瘤技術股份有限公司 | Bridged bicyclic inhibitors of menin-mll and methods of use |
PT3429591T (en) | 2016-03-16 | 2023-06-21 | Univ Michigan Regents | Substituted inhibitors of menin-mll and methods of use |
CA3022868A1 (en) | 2016-05-02 | 2017-11-09 | Shaomeng Wang | Piperidines as menin inhibitors |
BR122024002146A2 (en) | 2016-06-10 | 2024-03-05 | Vitae Pharmaceuticals, Inc. | COMPOUNDS INHIBITING THE INTERACTION OF MENINA-LLM AND THE CRYSTALLINE FORM OF THESE |
AR109658A1 (en) | 2016-09-16 | 2019-01-09 | Vitae Pharmaceuticals Inc | MENINA-MLL INTERACTION INHIBITORS |
WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
CN110691779B (en) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | Method for treating hematological malignancies and ewing's sarcoma |
SG11201909083UA (en) | 2017-03-31 | 2019-10-30 | Univ Michigan Regents | Piperidines as covalent menin inhibitors |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
TW201920170A (en) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | Substituted inhibitors of MENIN-MLL and methods of use |
WO2019189732A1 (en) | 2018-03-30 | 2019-10-03 | 大日本住友製薬株式会社 | Optically active crosslinked cyclic secondary amine derivative |
CN113164443A (en) | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | Treatment of hematologic malignancies with multiple endocrine oncostatin inhibitors |
-
2017
- 2017-05-02 CA CA3022868A patent/CA3022868A1/en not_active Abandoned
- 2017-05-02 AU AU2017259436A patent/AU2017259436B2/en not_active Ceased
- 2017-05-02 ES ES17722968T patent/ES2899936T3/en active Active
- 2017-05-02 BR BR112018072570A patent/BR112018072570A2/en not_active IP Right Cessation
- 2017-05-02 SG SG11201809714TA patent/SG11201809714TA/en unknown
- 2017-05-02 CN CN201780040586.6A patent/CN109415337B/en active Active
- 2017-05-02 US US16/098,147 patent/US10899738B2/en active Active
- 2017-05-02 EP EP17722968.9A patent/EP3452461B1/en active Active
- 2017-05-02 MX MX2018013433A patent/MX2018013433A/en unknown
- 2017-05-02 JP JP2018557418A patent/JP6991585B2/en active Active
- 2017-05-02 KR KR1020187034933A patent/KR20190015275A/en not_active Application Discontinuation
- 2017-05-02 WO PCT/US2017/030577 patent/WO2017192543A1/en unknown
-
2018
- 2018-10-31 IL IL262697A patent/IL262697B/en active IP Right Grant
-
2020
- 2020-11-23 US US17/101,323 patent/US20210198237A1/en not_active Abandoned
-
2021
- 2021-03-02 IL IL281182A patent/IL281182A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2017259436B2 (en) | 2021-08-26 |
BR112018072570A2 (en) | 2019-02-19 |
KR20190015275A (en) | 2019-02-13 |
US10899738B2 (en) | 2021-01-26 |
IL262697A (en) | 2018-12-31 |
WO2017192543A1 (en) | 2017-11-09 |
AU2017259436A1 (en) | 2018-12-20 |
US20210198237A1 (en) | 2021-07-01 |
ES2899936T3 (en) | 2022-03-15 |
CA3022868A1 (en) | 2017-11-09 |
EP3452461B1 (en) | 2021-09-08 |
CN109415337A (en) | 2019-03-01 |
CN109415337B (en) | 2022-01-18 |
MX2018013433A (en) | 2019-07-18 |
JP2019514950A (en) | 2019-06-06 |
IL262697B (en) | 2021-04-29 |
US20190152947A1 (en) | 2019-05-23 |
IL281182A (en) | 2021-04-29 |
EP3452461A1 (en) | 2019-03-13 |
JP6991585B2 (en) | 2022-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
SG11201808729WA (en) | Bet protein degraders | |
SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
SG11201808728QA (en) | Mdm2 protein degraders | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201804934PA (en) | Novel Compounds | |
SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201807708SA (en) | Estrogen receptor modulators | |
SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |